2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Drs Kitko and Patel discuss graft-versus-host disease recognition, treatment selection, and ongoing research with novel agents and biomarkers of response.
Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Sanofi, we had the pleasure of speaking with Carrie L. Kitko, MD, and Sagar S. Patel, MD, to contribute to the discussion around optimal disease management and research in graft-vs-host-disease (GVHD).
Kitko is an associate professor of pediatrics, the medical director of the Pediatric Stem Cell Transplantation Program, and the Ingram Professor of Pediatric Oncology at Monroe Carell Jr. Children’s Hospital at Vanderbilt in Nashville, Tennessee. Patel is the director of Communications and Media Relationships for the Division of Hematology at the University of Utah Huntsman Cancer Institute in Salt Lake City.
On February 17, 2024, the GVHD Alliance held the Second Annual GVHD Day, flooding Twitter with the hashtag #GVHDDay in recognition of all those who are affected by GVHD. In our exclusive interview, Kitko and Patel discussed the signs of disease recognition, principles around treatment selection, and ongoing research with novel agents and biomarkers of response.
___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by Sanofi. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air.
*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.